Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Mendelian Randomization Reveals Potential Drug Targets for Multiple Sclerosis Targeting Ferroptosis
Tao Wu1, Yuze Cao2, Lihua Wang3
1Department of Neurology, Peking University First Hospital, Beijing, China.
Introduction:
Multiple sclerosis (MS) is a multifactorial autoimmune condition, and existing medications offer limited efficacy, especially regarding the control of disease progression. Our previous research has suggested a significant role for ferroptosis in the mechanism of MS, making it a promising therapeutic target.
Methods:
To identify potential treatment targets related to ferroptosis, we conducted Mendelian randomization analysis. We used transcription and proteomic data for 511 ferroptosis-related proteins extracted from 49 tissues in GTEx v8 and deCODE data to derive genetic instruments. We conducted Mendelian randomization based on summary-level data from the International MS Genetics Consortium (47,429 cases and 68,374 controls). Reverse Mendelian randomization, Steiger filtering, Bayesian colocalization, constrained maximum likelihood, and model averaging-based (cML-MA) method, and phenomewide scanning were performed to strengthen findings. Additionally, we explored protein-protein interaction networks to uncover possible links between target proteins and approved MS therapeutics.
Results:
Under Bonferroni significance (P < 1.52 × 10-4), Mendelian randomization using cisexpression quantitative trait locus instruments revealed nine ferroptosis-related proteins (STAT3, MAPK1, MAPK3, MAP3K11, CISD2, KEAP1, ZEB1, PVT1, PARP1) with significant results in at least one tissue. Bayesian colocalization indicated that four of them (STAT3, PP.H4=0.97; MAPK1, PP.H4=0.95; MAPK3, PP.H4=0.99; ZEB1, PP.H4=0.96) share variation with MS. Under Bonferroni significance (P < 1.11 × 10-3), two proteins also obtained significant proteomic results (STAT3, P = 1.18 × 10-13, MAPK3, P = 3.25 × 10-8). Regional association analysis and phenomewide Scanning suggest a potential involvement of STAT3 in MS. STAT3 and MAPK3 interact with target proteins of current MS drugs, particularly STAT3.
Discussion:
These findings highlight the causal involvement of ferroptosis pathways in MS pathogenesis, emphasizing STAT3 and MAPK3 as promising therapeutic candidates. This work broadens current understanding of MS biology and suggests new directions for targeted drug development focused on ferroptosis regulation.
Conclusion:
Our analysis indicates that genetically predicted ferroptosis-related protein levels of STAT3, MAPK1, MAPK3, and ZEB1 are associated with MS risk. Among them, STAT3 and MAPK3 emerge as potential therapeutic candidates, with STAT3 warranting particular clinical investigation.
Insights
This study identifies STAT3 and MAPK3 as key proteins in multiple sclerosis (MS) pathogenesis through ferroptosis pathways. These findings suggest STAT3 and MAPK3 as promising therapeutic targets for MS drug development.
Area of Science:
- Genetics
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a complex autoimmune disease with limited treatment options for disease progression.
- Ferroptosis, a regulated cell death pathway, has been implicated in MS pathogenesis.
- Identifying novel therapeutic targets is crucial for improving MS management.
Purpose of the Study:
- To investigate the role of ferroptosis-related proteins in MS using a Mendelian randomization approach.
- To identify potential therapeutic targets for MS by analyzing genetic associations with ferroptosis pathways.
- To explore the link between ferroptosis-related proteins and existing MS therapeutics.
Main Methods:
- Mendelian randomization analysis using genetic data from GTEx v8, deCODE, and the International MS Genetics Consortium.
- Analysis of transcription and proteomic data for 511 ferroptosis-related proteins across 49 tissues.
- Application of techniques including reverse Mendelian randomization, Bayesian colocalization, and phenomewide scanning.
- Exploration of protein-protein interaction networks to identify links with approved MS drugs.
Main Results:
- Nine ferroptosis-related proteins, including STAT3, MAPK1, MAPK3, and ZEB1, showed significant associations with MS risk.
- Four proteins (STAT3, MAPK1, MAPK3, ZEB1) demonstrated shared genetic variation with MS.
- STAT3 and MAPK3 were identified as potential therapeutic targets, with STAT3 showing a strong association and interaction with current MS drug targets.
- Protein-protein interaction analysis revealed connections between STAT3 and MAPK3 with targets of existing MS medications.
Conclusions:
- Ferroptosis pathways causally contribute to MS pathogenesis.
- STAT3 and MAPK3 are highlighted as promising therapeutic candidates for MS.
- This research offers new insights into MS biology and directs future drug development towards ferroptosis regulation.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu